Obagi Medical has unveiled significant new clinical data regarding its line of hyaluronic acid injectables during the American Society for Dermatologic Surgery (ASDS) Annual Meeting. The event took place from November 13 to 16, 2025, in Chicago, Illinois. This research highlights the effectiveness of Obagi’s hyaluronic acid fillers in enhancing midface volume and improving the appearance of nasolabial folds.
At the meeting, a pivotal study comparing two hyaluronic acid fillers for midface augmentation was presented, underscoring the clinical relevance of Obagi’s products. The study, which involved a comprehensive evaluation of patient outcomes, showcased the fillers’ ability to provide noticeable improvements in facial aesthetics. This work earned recognition as one of the top ten abstracts, presented by esteemed dermatologist Dr. Sue Ellen Cox.
The data presented is particularly relevant for practitioners in the field of dermatology and aesthetic medicine. According to the study, patients reported increased satisfaction with their facial appearance after treatment with Obagi’s hyaluronic acid injectables. The results also indicated a favorable safety profile, which is crucial for both patients and healthcare providers.
Implications for Aesthetic Medicine
Obagi Medical, a prominent player in the physician-dispensed skincare market and a subsidiary of Waldencast plc, is known for its commitment to innovation in aesthetic solutions. The findings presented at the ASDS Annual Meeting reinforce the company’s position as a leader in this competitive industry.
The FDA study’s outcomes are expected to guide clinicians in making informed decisions about midface augmentation procedures. By demonstrating the effectiveness of Obagi’s hyaluronic acid fillers, the research may influence treatment protocols and patient education, ultimately enhancing the quality of care delivered.
As the demand for non-surgical aesthetic treatments continues to grow, the new data from Obagi Medical serves as a timely contribution to the ongoing dialogue within the dermatological community. The recognition received at the ASDS Annual Meeting further solidifies the credibility of Obagi’s products and their role in modern aesthetic practices.
In conclusion, the insights shared by Obagi Medical at the ASDS Annual Meeting not only highlight the efficacy of their hyaluronic acid injectables but also underscore the company’s ongoing commitment to advancing the field of aesthetic medicine. This research paves the way for more informed clinical practices and improved patient outcomes in the realm of cosmetic dermatology.
